Renata, a prominent pharmaceutical company based in Bangladesh, has achieved a significant milestone by shipping the inaugural consignment of Levonorgestrel 1.5 mg to Australia.
This marks the entry of Renata’s first registered product into the Australian market, signaling the company’s expanding global footprint.
Levonorgestrel, branded as Novella-1, is a widely recognized oral emergency contraceptive pill approved by esteemed regulatory authorities such as the World Health Organization, the US Food and Drug Administration (FDA), and the Therapeutic Goods Administration (TGA).
Renata’s Levonorgestrel is manufactured and supplied from its TGA-approved potent product facility, ensuring adherence to stringent quality standards.
The distribution and commercialization of Novella-1 in Australia will be facilitated through Renata’s strategic partner, Nova Pharmaceuticals Australasia Pty Ltd. Nova Pharmaceuticals boasts an impressive track record of supplying pharmaceutical products to pharmacies and supermarkets across Australia for the past 18 years.
This collaboration leverages Nova Pharmaceuticals’ established market presence and Renata’s high-quality product offerings, creating a synergistic partnership.
With two additional products awaiting registration in Australia, Renata aims to strengthen its presence in the stringently regulated market.
